Buy Voveran SR

Voveran SR

Voveran SR: Diclofenac 100 mg Sustained-Release Pill - UK Overview

Therapeutic class: Pain Relief (non-steroidal anti-inflammatory drug - NSAID) Active ingredient: Diclofenac sodium Formulation: Sustained-release oral tablet (pill) - 100 mg per tablet Regulatory status (UK): Prescription-only medicine (POM) authorized by the Medicines and Healthcare products Regulatory Agency (MHRA)

This article covers diclofenac, the active ingredient in Voveran SR, and provides evidence-based patient information for adults in the United Kingdom.

How Voveran SR Works in the Body

Diclofenac belongs to the class of non-steroidal anti-inflammatory drugs. It inhibits the cyclo-oxygenase enzymes COX-1 and COX-2, which are required for the conversion of arachidonic acid into prostaglandins. Prostaglandins mediate inflammation, pain, and fever. By reducing prostaglandin synthesis, diclofenac diminishes the inflammatory response, alleviates pain, and lowers fever.

Because Voveran SR is a sustained-release formulation, the tablet dissolves slowly, providing a relatively steady plasma concentration over 24 hours. This allows once-daily dosing while maintaining effective pain control. The drug is well absorbed from the gastrointestinal tract, undergoes hepatic metabolism (primarily via CYP2C9), and is excreted in urine and feces.

Conditions Treated with Voveran SR

Voveran SR is authorised by the MHRA for the following adult indications:

• Relief of mild to moderate pain associated with musculoskeletal disorders (e.g., osteoarthritis, rheumatoid arthritis, low back pain, sprains).
• Management of postoperative pain where an NSAID is appropriate.

The medication is intended for patients who require anti-inflammatory and analgesic effects but for whom paracetamol alone is insufficient.

Patient Suitability and Contraindications

Who Should Use Voveran SR?

• Adults with acute or chronic inflammatory pain where an NSAID is indicated.
• Patients who can tolerate oral medication and have no contraindicating health conditions.

Absolute Contraindications

• Known hypersensitivity to diclofenac, any other NSAID, or any excipients in the tablet.
• History of asthma, urticaria, or anaphylaxis triggered by aspirin or other NSAIDs.
• Active or recurrent gastric/duodenal ulceration or gastrointestinal bleeding.
• Severe heart failure (NYHA class III-IV) or recent myocardial infarction.
• Third-trimester pregnancy (diclofenac is contraindicated in late pregnancy).

Relative Contraindications / Precautions

• Moderate renal impairment (creatinine clearance < 60 mL/min).
• Moderate hepatic impairment.
• Uncontrolled hypertension.
• Concomitant use of anticoagulants (e.g., warfarin) or antiplatelet agents (e.g., aspirin).
• Use in the first trimester of pregnancy - only if the benefit outweighs risk and advised by a clinician.

Patients with any of the above conditions should discuss alternatives with their prescriber.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Upper abdominal discomfort, dyspepsia, or heartburn (often mitigated by taking the tablet with food).
• Headache or dizziness.
• Mild skin rash or itching.

These effects are usually transient and resolve without medical intervention.

Serious Adverse Events

• Gastrointestinal bleeding, perforation, or ulceration (may present as black stools or severe abdominal pain).
• Cardiovascular events such as myocardial infarction or stroke, particularly with long-term use.
• Acute kidney injury manifested by reduced urine output or swelling.
• Severe skin reactions (e.g., Stevens-Johnson syndrome) - seek urgent care if rash spreads or blisters develop.

Drug Interactions

• Anticoagulants / Antiplatelet agents - increased risk of bleeding; monitoring of INR is advised.
• ACE inhibitors, ARBs, or diuretics - may reduce renal perfusion; renal function should be checked.
• Lithium - diclofenac can raise serum lithium levels; dose adjustment may be required.
• Methotrexate - NSAIDs may reduce renal clearance of methotrexate, raising toxicity risk.
• Other NSAIDs or COX-2 inhibitors - additive gastrointestinal and renal toxicity; avoid concurrent use.

Food and Lifestyle Interactions

• Take Voveran SR with a full glass of water and preferably with meals to minimise gastrointestinal irritation.
• Alcohol can potentiate gastric mucosal damage; limit intake while on therapy.
• Driving or operating machinery is generally not impaired, but dizziness may occur in susceptible individuals.

If you are uncertain about any medication, supplement, or herbal product you are taking, inform your healthcare provider before starting Voveran SR.

Dosing and Administration Guidelines

• Standard adult dose: One 100 mg sustained-release tablet taken once daily with food.
• Swallow the tablet whole; do not crush, chew, or split, as this would destroy the controlled-release mechanism.
• If a dose is missed, take it as soon as remembered unless it is near the time of the next scheduled dose. Do not double the dose.
• Renal or hepatic impairment: Dose reduction or alternative therapy may be necessary; the prescriber will adjust based on laboratory results.
• Elderly patients: Start at the lowest effective dose and monitor for adverse effects, especially gastrointestinal and renal complications.

Overdose - symptoms may include nausea, vomiting, abdominal pain, and drowsiness. Seek emergency medical attention; treatment is primarily supportive, and activated charcoal may be considered if presentation is early.

Discontinuation - abrupt cessation is generally safe, but prolonged therapy should be tapered under medical supervision to monitor for rebound pain or inflammation.

Monitoring and Follow-Up

• Renal function: Serum creatinine and eGFR at baseline and periodically during long-term therapy.
• Liver enzymes: ALT and AST may be checked if hepatic disease is present.
• Gastrointestinal safety: Patients with risk factors should be assessed for ulcer symptoms; prophylactic proton-pump inhibitors may be prescribed.
• Cardiovascular risk: Blood pressure and lipid profile should be monitored in patients with existing cardiovascular disease.

Regular review with a prescriber ensures that benefits continue to outweigh risks.

Storage and Handling

• Store tablets at room temperature (15-30 °C) in a dry place, away from direct sunlight and moisture.
• Keep the container tightly closed and out of reach of children.
• Do not use tablets after the expiry date printed on the pack.
• Dispose of unused medication via a pharmacy take-back scheme or follow local NHS disposal guidelines.

Medication-Specific Glossary

Cyclo-oxygenase (COX)

Enzymes (COX-1 and COX-2) that convert arachidonic acid into prostaglandins, which promote inflammation, pain, and fever.

Sustained-Release (SR) Tablet

A formulation designed to release the active drug slowly over an extended period, allowing once-daily dosing.

Prostaglandin

Lipid compounds that act locally to mediate inflammation, pain perception, and gastric mucosal protection.

Gastro-intestinal (GI) Ulcer

A breach in the lining of the stomach or duodenum, often precipitated by NSAID-induced inhibition of protective prostaglandins.

Renal Clearance

The volume of plasma from which a substance is completely removed by the kidneys per unit time; important for dosing adjustments in kidney disease.

Medical Disclaimer

This article provides educational information about Voveran SR and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.